Economy · News reference
Royalty Pharma will pay Zealand Pharma $100 million for economic rights tied to rusfertide, with FDA action expected in Q3 of 2026.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
$1 billion investment will grow AstraZeneca’s workforce in Massachusetts by over 50% and deliver next-generation medicinesAstraZeneca today announced the opening of its newest global strategic research and development
AstraZeneca & Daiichi Sankyo team up with Summit Therapeutics to test Datroway + ivonescimab combo in triple-negative breast cancer.
Europe's cancer metabolism-based therapeutics market is projected to grow from $1.12 billion in 2026 to $8.54 billion by 2035, representing a 25.3% CAGR. Growth is driven by Europe's high cancer burden, advances in molecular profiling, precision oncology adoption, and regulatory validation. Small molecules and oral administration routes dominate, with breast cancer and non-small cell lung cancer as leading indications. Key players include AstraZeneca, Bayer, Novartis, Roche, and Servier.
Royalty Pharma (RPRX) offers investors diversified exposure to blockbuster drugs through a unique royalty-based investment model. With strong returns on invested capital (14.9% average ROIC), ownership in 16 blockbuster drugs, and analyst forecasts suggesting significant multiple expansion potential, the stock appears undervalued despite a 50% year-to-date surge. However, risks include share dilution and increasing competition in the pharma royalty space.